Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Carvedilol Drug Market size is poised to witness lucrative growth rate during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the increasing prevalence of cardiac diseases that result in heart failure, along with the growing cases of hypertension across the globe. Poor lifestyle is prevalent amongst the masses, including high sugar intake, lack of exercise, stressful lifestyle, and consumption of processed food, which is the primary cause of high blood pressure and cardiovascular diseases. According to the statistics by the World Health Organization (WHO), cardiovascular diseases killed 17.9 million people in 2019, which represents 32% of all deaths globally. Along with this, hypertension is another serious disease, which is known to affect over 1.28 billion adults aged 30-79 years worldwide. Carvedilol is only given to clinically stable patients in case of heart failure, as it is a non-selective adrenergic blocker, which cannot be given as a prescription medication. Moreover, the growing incidences of heart failure is also expected to drive the market growth. In addition to this, the carvedilol drug market growth is projected to increase on the back of increasing medical R&D, along with the emergence of new and advanced medical technologies.
Carvedilol Drug Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Cardiovascular Diseases
- High Mortality Rate from Heart Failure
- Prevalence of Poor Lifestyle among Masses
Challenges
- Side Effects, such as, Dizziness, and Tiredness
- Risk in Consumption during Pregnancy
Carvedilol Drug Market: Key Insights
Base Year |
2023 |
Forecast Year |
2024–2036 |
Regional Scope |
|
Carvedilol Drug Segmentation
The market is segmented by application into high blood pressure, congestive heart failure (CHF), ventricular dysfunction, and others, out of which, the congestive heart failure (CHF) segment is anticipated to hold a substantial share in the global carvedilol drug market over the forecast period on account of increasing prevalence of CHF. CHF is caused when muscles in the heart are unable to pump, mostly due to fluid build-up in the heart. High levels of cholesterol is the most prominent contributing factor for congestive heart failure.
Our in-depth analysis of the global market includes the following segments:
By Product |
|
By Application |
|
By Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportCarvedilol Drug Industry - Regional Synopsis
Asia Pacific industry is expected to account for largest revenue share by 2037, driven by rising prevalence of hypertension in low and middle income countries. As per a WHO report, two-third of the total hypertension cases occur in low- and middle-income countries.
The carvedilol drug market in the North America region is anticipated to gain the largest revenue share throughout the forecast period owing to the high prevalence of heart failure and high blood pressure, along with the presence of efficient healthcare infrastructure in the region. According to the data by the Center for Disease Control and Prevention (CDC), heart failure was the cause for 379,800 deaths in 2018. Moreover, 116 million adults have hypertension in the United States.

Companies Dominating the Carvedilol Drug Landscape
- Sun Pharmaceutical Industries Limited
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- Sanofi-aventis Groupe
- Abbott Laboratories
- Merck & Co., Inc.
- Siemens Healthcare GmbH
- Amgen Inc.
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Pfizer Inc.
In the News
-
June 02, 2021: Sun Pharmaceutical Industries Limited entered a collaborative agreement with Ferring Pharmaceuticals Pvt. Ltd. (Ferring), a Switzerland-based biopharmaceuticals MNC, to commercialize a room temperature stable formulation of obstetric drug, CARITEC (Carbetocin RTS) in India.
-
April 28, 2021: Merck Sharp & Dohme Corp. announced the complete acquisition of Pandion Therapeutics. After this acquisition, Pandion Therapeutics became a wholly-owned subsidiary of Merck Sharp & Dohme Corp.
Author Credits: Radhika Pawar
- Report ID: 4019
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT